ClinicalTrials.gg
CompletedNCT01692886Updated Jun 2, 2026

A Study Evaluating 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) In Healthy Infants In China

A Phase 3 interventional study of 7-valent Pneumococcal Conjugate Vaccine and 13-valent Pnumococcal Conjugate vaccine in Pneumococcal Infection, sponsored by Pfizer. Completed at 4 sites in China. Open to participants aged 42 Days to 77 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-02.

Sponsored by Pfizer · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,674
Allocation
Randomized
Ages
42 Days to 77 Days
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections — none open to participants now, 1 under way, none of them phase 3. 13-valent pneumococcal vaccine · Pneumococcal Infections.

Enrollment
5th of 44
1,674 · median 328
Started
2012
with 5 others
Phase 3
19 of 44
none open now
Registered
19th of 44
by date
Lead sponsor
16 of 44
Pfizer

Among the 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections, this one is the 5th largest by enrollment, is one of 6 that started in 2012, is one of 19 in phase 3, and was the 19th registered.

Pneumococcal Infections

298 studies on the registry are indexed under Pneumococcal Infections; 25 are open to participants now.

Browse Pneumococcal Infections studies →

Open to participants now

None of the 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections is open now. The open studies under Pneumococcal Infections, anywhere →

About 13-valent pneumococcal vaccine

13-valent pneumococcal vaccine: first FDA approval 2010 (Prevnar 13). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.

This study: 42 Days to 77 Days · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections as a file.
02

Study summary

This study is primarily designed to evaluate the IgG immune responses to the 13 pneumococcal serotypes induced by 13vPnC compared with the immune responses induced by 7vPnC when measured 1 month after the infant series, and to evaluate the acceptability of the safety profile of 13vPnC as measured by the incidence rates of local reactions, systemic events and adverse events.

03

Conditions studied

  • Pneumococcal Infection

Keywords

  • 13vPnC
  • 7vPnC
  • Healthy subjects
  • China
04

Who can participate

Ages eligible
42 Days to 77 Days
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 42 to 77 days (approximately 2 months) at the time of enrollment.
  2. Healthy infant as determined by medical history, physical examination, and judgment of the investigator.

Exclusion criteria

Exclusion Criteria:

  1. Previous vaccination with licensed or pneumococcal vaccine.
  2. A previous anaphylactic reaction to any vaccine or vaccine-related component.
  3. to vaccination with pneumococcal vaccines.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,674 participants (actual)

Study arms

  • Active comparator
    7vPnC (3-, 4-, 5-, 12-Month)

    Biological: 7-valent Pneumococcal Conjugate Vaccine

  • Experimental
    13vPnC (3-, 4-, 5-, 12-Month)

    Biological: 13-valent Pnumococcal Conjugate vaccine

  • Experimental
    13vPnC (2-, 4-, 6-, 12-Month)

    Biological: 13-valent Pnumococcal Conjugate vaccine

  • Experimental
    13vPnC (3-, 5-, 12-Month)

    Biological: 13-valent Pnumococcal Conjugate vaccine

Interventions

  • suspension in prefilled syringe for intramuscular injection; 0.5 mL; one dose at 3-Month Visit, 4-Month Visit, 5-Month Visit, and 12-Month Visit, respectively

    Also known as: 7vPnC

  • suspension in prefilled syringe for intramuscular injection; 0.5 mL; one dose at 3-Month Visit, 4-Month Visit, 5-Month Visit, and 12-Month Visit, respectively

    Also known as: 13vPnC

  • suspension in prefilled syringe for intramuscular injection; 0.5 mL; one dose at 2-Month Visit, 4-Month Visit, 6-Month Visit, and 12-Month Visit, respectively

    Also known as: 13vPnC

  • suspension in prefilled syringe for intramuscular injection; 0.5 mL; one dose at 3-Month Visit, 5-Month Visit, and 12-Month Visit, respectively

    Also known as: 13vPnC

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level ≥0.35 mcg/mL 1 Month After the Infant Series in Group 1 And Group 2.

    Time frame: 1 month after the infant series (6 Months of age)

  2. Percentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level ≥0.35 mcg/mL 1 Month After the Infant Series in Group 3.

    Time frame: 1 month after the infant series (7 Months of age)

  3. Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After the Infant Series in Group 1 and Group 2.

    Time frame: 1 month after the infant series (6 Months of age)

  4. Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After the Infant Series in Group 3.

    Time frame: 1 month after the infant series (7 Months of age)

  5. Percentage of Participants Reporting Adverse Events in Group 1 and Group 2.

    Time frame: Approximately 16 months from the participation into the study to the end of study

  6. Percentage of Participants Reporting Adverse Events in Group 3 and Group 4.

    Time frame: Approximately 16 months from the participation into study to the end of study

  7. Percentage of Participants Reporting Pre-Specified Local Reactions In the 7 Days After Each Pneumococcal Vaccination in Group 1 and Group 2.

    Time frame: Seven days after each pneumococcal vaccination dose within the period up to 12 months

  8. Percentage of Participants Reporting Pre-Specified Local Reactions In the 7 Days After Each Pneumococcal Vaccination in Group 3 and Group 4.

    Time frame: Seven days after each pneumococcal vaccination dose within the period up to 12 months

  9. Percentage of Participants Reporting Pre-Specified Systemic Events (Including The Use Of Antipyretic Medication) In the 7 Days After Each Pneumococcal Vaccination in Group 1 and Group 2.

    Time frame: Seven days after each pneumococcal vaccination dose within the period up to 12 months

  10. Percentage of Participants Reporting Pre-Specified Systemic Events (Including The Use Of Antipyretic Medication) In the 7 Days After Each Pneumococcal Vaccination in Group 3 and Group 4.

    Time frame: Seven days after each pneumococcal vaccination dose within the period up to 12 months

Secondary outcomes

  1. Percentage of Participants In A Subset Achieving Serotype-specific Opsonophagocytic Activity (OPA) Titer ≥ Lower Limit Of Quantitation (LLOQ) 1 Month After the Infant Series in Group 1 And Group 2.

    Time frame: 1 month after the infant series (6 Months of age)

  2. Percentage of Participants In A Subset Achieving Serotype-specific Opsonophagocytic Activity (OPA) Titer ≥ Lower Limit Of Quantitation (LLOQ) 1 Month After the Infant Series in Group 3.

    Time frame: 1 month after the infant series (7 Months of age)

  3. Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titer (GMT) 1 Month After the Infant Series in Group 1 and Group 2.

    Time frame: 1 month after the infant series (6 Months of age)

  4. Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titer (GMT) 1 Month After the Infant Series in Group 3.

    Time frame: 1 month after the infant series (7 Months of age)

  5. Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After the Toddler Dose in Group 2 and Group 3.

    Time frame: 1 month after the toddler dose (13 Months of age)

  6. Percentage of Participants In A Subset Achieving Serotype-specific Opsonophagocytic Activity (OPA) Titer ≥ Lower Limit Of Quantitation (LLOQ) 1 Month After the Toddler Dose in Group 2 and Group 3.

    Time frame: 1 month after the toddler dose (13 Months of age)

  7. Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titer (GMT) 1 Month After the Toddler Dose in Group 2 and Group 3.

    Time frame: 1 month after the toddler dose (13 Months of age)

  8. Percentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level ≥0.35 mcg/mL 1 Month After the Infant Series in Group 4.

    Time frame: 1 month after the infant series (6 Months of age)

  9. Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After the Infant Series in Group 4.

    Time frame: 1 month after the infant series (6 Months of age)

  10. Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After the Toddler Dose in Group 4.

    Time frame: 1 month after the toddler dose (13 Months of age)

  11. Percentage of Participants In A Subset Achieving Serotype-specific Opsonophagocytic Activity (OPA) Titer ≥ Lower Limit Of Quantitation (LLOQ) 1 Month After the Infant Series in Group 4.

    Time frame: 1 month after the infant series (6 Months of age)

  12. Percentage of Participants In A Subset Achieving Serotype-specific Opsonophagocytic Activity (OPA) Titer ≥ Lower Limit Of Quantitation (LLOQ) 1 Month After the Toddler Dose in Group 4.

    Time frame: 1 month after the toddler dose (13 Months of age)

  13. Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titer (GMT) 1 Month After the Infant Series in Group 4.

    Time frame: 1 month after the infant series (6 Months of age)

  14. Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titer (GMT) 1 Month After the Toddler Dose in Group 4.

    Time frame: 1 month after the toddler dose (13 Months of age)

07

Study locations

4 sites
  • Jiangsu Province Guanyun County Center for Disease prevention and Control
    Guanyun County,, Jiangsu 222200, China
  • Jiangsu Province Huaiyin District Center for Disease prevention and Control
    Huaian City,, Jiangsu 223300, China
  • Jiangsu Province Hongze County Center for Disease prevention and Control
    Huaian City, Jiangsu 223100, China
  • Jiangsu Province Lianshui County Center for Disease prevention and Control
    Lianshui County, Jiangsu 223400, China
08

References and documents

Publications

  • Zhu F, Hu Y, Li J, Ye Q, Young MM Jr, Liang JZ, Gruber WC, Giardina PC, Scott DA. Immunogenicity and Safety of the 13-Valent Pneumococcal Conjugate Vaccine Administered in a 3 + 1 versus 2 + 1 Dose Schedule Among Infants in China. Pediatr Infect Dis J. 2019 Nov;38(11):1150-1158. doi: 10.1097/INF.0000000000002458. PubMed 31626050 ↗
  • Zhu F, Hu Y, Li J, Ye Q, Young MM Jr, Zhou X, Chen Z, Yan B, Liang JZ, Gruber WC, Giardina PC, Scott DA. Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine Compared With 7-valent Pneumococcal Conjugate Vaccine Among Healthy Infants in China. Pediatr Infect Dis J. 2016 Sep;35(9):999-1010. doi: 10.1097/INF.0000000000001248. PubMed 27254028 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2012, a primary completion of Apr 2014 and a completion of Apr 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2012
First posted
Sep 25, 2012
Start
Sep 2012
Primary completionActual
Apr 2014
CompletionActual
Apr 2014
Last update
Jun 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01692886
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Sep 25, 2012
Start date
Sep 2012
Primary completion
Apr 2014
Completion
Apr 2014
Last update
Jun 2, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: 13-valent pneumococcal vaccine

Start the discussion